Chronix Biomedical
The company plans to transition its DetermaIO test from research to clinical use and to launch a new research product for immunotherapy monitoring by the end of this year.
Oncocyte to Acquire Chronix Biomedical
The move will add Chronix's proprietary technology for blood-based immune therapy monitoring and transplant rejection testing to Oncocyte's existing test menu.
Oncocyte, Chronix Enter Licensing, Collaboration Agreement for Liquid Biopsy Technology
Oncocyte is licensing Chronix's blood-based copy number instability test, and Chronix will help commercialize Oncocyte's DetermaRx in the EU through its German lab.